Astrana Health, Inc.

NASDAQ:ASTH

Medical - Care Facilities

Healthcare
$29.65 +2.70%

+$1.03 today

Market cap
$1.47B
Beta
0.94
P/E (TTM)
63.3
EPS (TTM)
$0.62
52W Low $18.08High $40.13

Volume 0.52M

Average 0.51M

ASTH EBITDA Margin

EBITDA as a percentage of revenue.

Astrana Health, Inc.NASDAQ: ASTH

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to 5.3%

EBITDA Margin was 5.3% in Q1 FY2026, up 1.5 pp from a year earlier. On a trailing-twelve-month basis it was 4.6%, down 1.1 pp year over year. Over 3 fiscal years it narrowed by 5.5 pp.

Context

  • EBITDA Margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 8 analysts of 4.5% for the fiscal year ending Dec 2026, up from 4.3% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
5.3%+1.0 pp QoQ
Last fiscal yearDec 2025
4.3%-2.7 pp YoY
LTMMar 2026
4.6%-1.1 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1.5 pp+1.1 pp-0.3 pp
1 year-2.7 pp+0.2 pp+3.0 pp
3 years-5.5 pp+1.4 pp+6.9 pp
5 years+2.7 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
4.3%
Year-over-year change
-2.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How ASTH compares with its peers on the latest reported figures

  • ASTH's LTM Mar 2026 EBITDA Margin of 4.6% is the 2nd highest of the 4 companies compared; the peer median is 2.9%.
  • Its year-over-year change of -1.1 pp is the 2nd highest of 4, against a peer median of -1.1 pp.
  • Over three fiscal years its change of -5.5 pp compares with a peer median of +3.6 pp.
ASTH Competitors Peer median
EBITDA Margin for ASTH and competitors
Company Period LTM level YoY 3-year change
NUTXNutex Health, Inc.LTM Mar 202633.2% -1.1 pp+212.5 pp
ASTHAstrana Health, Inc.LTM Mar 20264.6% -1.1 pp-5.5 pp
PRVAPrivia Health Group, Inc.LTM Jun 20262.9% +0.9 pp+3.6 pp
AGLAgilon Health, Inc.LTM Mar 2026-5.9% -2.2 pp-3.2 pp
Peer median (excluding ASTH) 2.9%-1.1 pp+3.6 pp

Competitors are the stored peer set for ASTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue773.92M1.14B1.39B2.03B3.18B
Cost of Revenue596.14M944.69M1.17B1.76B2.89B
Gross Profit177.77M199.48M214.96M271.39M295.78M
Gross Margin23.0%17.4%15.5%13.3%9.3%
Research & Development00000
Selling, General & Admin62.08M77.67M112.6M154.11M217.26M
Operating Expenses79.59M95.21M130.35M182.04M217.26M
Depreciation & Amortization17.52M17.54M17.75M27.93M45.75M
EBITDA100.66M112.08M123.69M141.84M135.28M
EBITDA Margin13.0%9.8%8.9%7.0%4.3%
Operating Income98.18M104.27M84.61M89.35M78.53M
Operating Margin12.7%9.1%6.1%4.4%2.5%
Interest Income1.57M1.98M14.21M14.51M12.16M
Interest Expense5.39M7.92M16.1M33.1M49.93M
Other Income / Expenses(20.43M)(17.65M)5.23M(8.53M)(38.92M)
Income Before Tax77.75M86.62M89.84M80.82M39.61M
Pre-Tax Margin10.0%7.6%6.5%4.0%1.2%
Income Tax Expense31.69M40.88M31.99M30.89M15.53M
Net Income68.92M45.17M60.72M43.15M22.49M
Net Margin8.9%3.9%4.4%2.1%0.7%
EPS (Basic)1.571.001.300.910.46
EPS (Diluted)1.520.991.290.900.46
Weighted Avg Shares43.83M44.97M46.71M47.69M49.08M
Weighted Avg Shares (Diluted)45.4M45.6M47.07M48.22M49.37M

Astrana Health, Inc.

NASDAQ:ASTH

Intrinsic Alpha fair value

Locked

Current Price

$29.65

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.